+39 02 610346.1 - info@newron.com

Luca Benatti

Luca Benatti

Luca is CEO & Director in the Board of Directors of EryDel S.p.A. He has over 25 year experience in Pharma and Biotech. He was Co-founder, CEO and Member of the Board of Newron until May 2012. Under his guidance, Newron developed a pipeline of innovative therapies, with the most advanced compound safinamide approved for the treatment of Parkinson's disease. During his tenure, Newron raised significant capital from international venture capital firms and was listed at the SIX Swiss exchange. He also was instrumental in finalizing multi-million licensing deals with Merck Serono, Meiji Seika and Zambon. He is Board member at Intercept Pharmaceuticals (ICPT), Chairman of Italian Angels for Biotech, Chairman of the Scientific Advisory Board of Zambon, member of the Board of Assobiotec - the Italian Biotech Association - and member of the jury of the European Biotechnica Award. Luca graduated and performed his post-doctoral training at Milano Genetics Institute. He has authored several scientific publications and holds numerous patents. Luca is member of the Company' Audit and Risk and Research and Development Committee. Luca is Italian.